Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL

Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia

The goal of this clinical research study is to find out if rhIL-11（Interleukin 11） may increase the platelet count in Childhood patients with acute lymphocytic leukemia (ALL) who develop low platelet counts while receiving standard CAT（cyclophosphamide+Cytosine arabinoside+mercaptopurine，7d） therapy.

Group A：patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL Group B：control group

Inclusion Criteria:

• new diagnosis of ALL
• TBIL≤34umol/L，Cr≤120umol/L，a normal EF
• age <18 years

Exclusion Criteria:

• patients with uncontrolled infection
• patients with Acute congestive heart failure or chronicity cardiorespiratory functional defect or serious cardiac arrhythmias